期刊文献+

MicroRNA Signaling Pathway Network in Pancreatic Ductal Adenocarcinoma 被引量:3

MicroRNA Signaling Pathway Network in Pancreatic Ductal Adenocarcinoma
原文传递
导出
摘要 Pancreatic ductal adenocarcinoma (PDAC) is considered to be the most lethal and aggressive malignancy with high mortality and poor prognosis. Their responses to current mnltimodal therapeutic regimens are limited. It is urgently needed to identify the molecular mechanism underlying pancreatic oncogenesis. Twelve core signaling cascades have been established critical in PDAC tumorigenesis by governing a wide variety of cellular processes. MicroRNAs (miRNAs) are aberrantly expressed in different types of tumors and play pivotal roles as post-transcriptional regulators of gene expression, Here, we will describe how miRNAs regulate different signaling pathways that contribute to pancreatic oncogenesis and progression, Pancreatic ductal adenocarcinoma (PDAC) is considered to be the most lethal and aggressive malignancy with high mortality and poor prognosis. Their responses to current mnltimodal therapeutic regimens are limited. It is urgently needed to identify the molecular mechanism underlying pancreatic oncogenesis. Twelve core signaling cascades have been established critical in PDAC tumorigenesis by governing a wide variety of cellular processes. MicroRNAs (miRNAs) are aberrantly expressed in different types of tumors and play pivotal roles as post-transcriptional regulators of gene expression, Here, we will describe how miRNAs regulate different signaling pathways that contribute to pancreatic oncogenesis and progression,
出处 《Journal of Genetics and Genomics》 SCIE CAS CSCD 2015年第10期563-577,共15页 遗传学报(英文版)
基金 supported by a fellowship from Tianjin Medical University General Hospital for his postdoctoral fellow research at MD Anderson Cancer Center
关键词 MICRORNA Signaling pathway TUMORIGENESIS Pancreatic ductal adenocarcinoma MicroRNA Signaling pathway Tumorigenesis Pancreatic ductal adenocarcinoma
  • 相关文献

参考文献7

二级参考文献80

  • 1Roel NUSSE.Wnt signaling in disease and in development[J].Cell Research,2005,15(1):28-32. 被引量:83
  • 2Legge F, Ferrandina G, Salutari V, et al, Biological characterization of ovarian cancer: prognostic and therapeutic implications. Ann Oncol, 2065,16 Suppl 4:iv95-iv101.
  • 3Agarwal R, Kaye SB, Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nat Rev Cancer, 2003,3:502-516.
  • 4Parker R J, Eastman A, Bostick-Bruton F, et al. Acquired cisplatin resistance in human ovarian cancer cells is associated with enhanced repair of cisplatin-DNA lesions and reduced drug accumulation. J Clin Invest, 1991,87:772-777.
  • 5Godwin AK, Meister A, O'Dwyer P J, et al. High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis. Proc Natl Acad Sci U S A, 1992,89:3070-3074.
  • 6Kelley SL, Basu A, Teicher BA, et al. Overexpression of metallo- thionein confers resistance to antJcancer drugs. Science, 1988,241:1813-1815.
  • 7Zheng T, Wang J, Chen X, et al. Role of microRNA drug resistance, Int J Cancer, 2010,126:2-10.
  • 8Ma J, Dong C, Ji C. MicroRNA and drug resistance. Ther, 2010.17: 523-31.
  • 9Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell, 2004,116:281-97.
  • 10Ambros V. The functions of animal microRNAs. Nature, 2004,431:350-5.

共引文献55

同被引文献3

引证文献3

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部